Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

NCT03803397 | Unknown Phase 1 DMC FDA Drug

• 1 other identifier: PV001-001 (Arm 1)
• Study Type: interventional
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

Autologous monocyte-derived dendritic cells pulsed with tumor lysate (PV-001-DC) will be given to a group of 3 people. If this is found to be safe, it will be given to up to 7 other people, for a total of up to 10 people in this arm. This will be the first study of PV-001-DC. Eligible patients must be progressing after having completed prior therapy with a PD-1/PD-L1 antagonist alone or in combination with anti-CTLA-4. If the patient is positive for BRAF, the patient must have progressed on at least one BRAF inhibitor in addition to a PD-1/PD-L1 inhibitor alone or in combination with CTLA-4 for metastatic melanoma. Although other kinds of dendritic cells (DCs) have been approved to treat some forms of cancer, they have not been approved to treat melanoma. PV-001-DC is a special kind of DCs that is combined with tumor lysate. The study procedures will start with the removal of a small amount of tumor tissue processed into protein fragments (lysate). There will also be collection of white blood cells through apheresis (a procedure in which blood is drawn from a patient and separated into its different cell types), the white blood cells will be collected and the remainder returned to the patient. Dendritic cells will be grown from the collected white blood cells and combined with the lysate to form PV-001-DC. On the first day of study treatment, patients will go to the clinic and have a needle placed in a vein. The PV-001-DC product will be infused into the patient's vein. Approximately every 3 weeks, for a total of 4 treatments, patients will receive additional infusions of PV-001-DC. Patients will be at the clinic for at least 1 hour following the end of the PV-001-DC infusion and if they feel fine, they may go home. Scans will be performed during the study at different times to see if their tumors have changed in size. Patients will also have their blood and small samples of tumors tested for changes to the immune system. After 365 days, the trial will be completed for that patient. Investigators will monitor patients carefully for any harmful side effects. The side effects in people cannot be completely known ahead of time

Conditions

Metastatic Melanoma

Outcome Measures

Primary Outcomes (1)

• Incidence and severity of Treatment-Emergent Adverse Events

  Treatment-Emergent Adverse Event Incidence in patients receiving IV infusion of PV-001-DC

  365 days

Secondary Outcomes (3)

• Overall Response Rate (ORR)

  365 days

• Progression-Free Survival (PFS)

  365 days

• Overall Survival (OS)

  365 days

Study Arms (1)

PV-001-DC alone

EXPERIMENTAL

Autologous Monocyte-derived Lysate Pulsed Dendritic Cells

Biological: PV-001-DC

Interventions

PV-001-DC BIOLOGICAL

Patient-specific cellular therapeutic for cancer immunotherapy

PV-001-DC alone

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Biopsy confirmed patients with un-resectable AJCC Stage III or IV melanoma who have measurable disease. Measurable disease is required, and is defined as tumor can be measured in two dimensions.
• Patient must have progressed with prior therapy with a PD-1 / PD-L1 antagonist alone or in combination with anti-CTLA-4. If the patient is positive for BRAF, the patient must have progressed on at least one BRAF inhibitor in addition to a PD-1 / PD-L1 inhibitor alone or in combination with CTLA4 for metastatic melanoma.
• Tumor specimens must be available for tumor lysates and immunological studies.
• ECOG Performance Status of ≤ 2 (corresponds to a Karnofsky Performance Status (KPS) of ≥ 70).
• Patients must be 18 years or older and able to give informed consent.
• Adequate bone marrow function of White Blood Cell (WBC) count to ≥ 1,500/uL; platelet count ≥ 100,000/mm3; absolute neutrophil count (ANC) \> 1,200/uL
• Patients must have adequate renal function by serum creatinine of ≤ 2.0 mg/dL.
• Adequate hepatic function of bilirubin ≤ 2.5 mg/dL; SGOT/SGPT \< 3× upper limit of normal (ULN).
• Patients must have the required wash out periods from prior therapy:
• Topical therapy: 2 weeks.
• Chemotherapy and radiotherapy: 4 weeks.
• Other investigational therapy: 4 weeks
• Patients of reproductive potential and their partners must agree to use an effective (\>90% reliability) form of contraception during the study and for 4 weeks following the last study drug.
• Women of reproductive potential must have a negative urine pregnancy test.
• Patients should have a life expectancy of \> 6 months.

You may not qualify if:

• Pre-existing autoimmune or antibody mediated disease including systemic lupus erythematous, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.
• Known history of human immunodeficiency virus (HIV) or any active immunosuppressive systemic infection or a suppressed immune system, including acquired immuno-deficiency syndrome (AIDS) or HIV positivity and known hepatitis infections (HCV or HBC), as assessed by serology.
• Patients on immunosuppressive therapy. Concurrent steroid use of not more than an equivalent of 10 mg of prednisone is allowed.
• Previous organ transplantation.
• Patients with active infection or with a fever \>101°F (38.5°C) within 3 days prior to the first scheduled treatment.
• Concurrent participation in other treatment related clinical studies. Non-treatment studies (e.g. observation or tumor cell analysis studies) are allowed.
• Prior malignancy (active within 3 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.
• o Significant cardiovascular disease (i.e., New York Heart Association (NYHA) class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).
• Female patients who are pregnant or lactating.
• Patients taken off Checkpoint Blockade agents: Ipilimumab, Nivolumab, Pembrolizumab, for Grade 3 or greater autoimmune toxicity.
• Patients who are positive for B-RafV600 mutation and are responding to targeted therapy.
• Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with his/her participation in the study, or to interfere with the interpretation of the results.
• Patients with endocrinopathy greater than grade III.
• Patients who have undergone a splenectomy in their previous medical history will be excluded from this trial. Evidence of a splenectomy will be from history or records.

Sponsors & Collaborators

• PrimeVax Immuno-Oncology Inc.: lead

MeSH Terms

Conditions

Melanoma

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Bruce Lyday

CONTACT

(714) 585-7485; bruce.lyday@primevax.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 31, 2018
• First Posted: January 14, 2019
• Study Start: April 1, 2024
• Primary Completion: August 30, 2024
• Study Completion: December 31, 2024
• Last Updated: July 6, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share